EU Biotech strategy: act faster for patients in Europe
EU Biotech strategy: act faster for patients in Europe
Today's press release from the European Commission on the Biotechnology Strategy has caused criticism from the Federal Association of Pharmaceutical Industry (BPI). Dr. Kai Joachimsen, General Managing Director of the BPI, complained that instead of reviews and evaluations, there are concrete measures for patients in Europe. He emphasized the need for a quick and decisive action in order not to lose connection in global competition.
The BPI basically welcomes the expansion of biotechnology in Europe. According to Joachimsen, many of the aspects mentioned could secure the location and possibly also strengthen sustainably. However, it is important to understand biotechnology as a handicraft of health care and to recognize it as a real location advantage. The proportion of biological biological medicines is increasing continuously and in Germany a total of 776 companies work with around 34,400 employees in this area. The expenditure for research and development was more than three billion euros in 2022.
The EU Commission calls important points in its strategy that can advance biotechnology in the EU, such as the transfer, production, tax incentives, regulative aspects, the protection of intellectual property, the extraction of specialists, the promotion of cooperation and financing. However, the strategy hardly deals with the question of the rapid market access of biotech products produced in the EU. There is also no answer to how existing production facilities can be secured or expanded by biopharmaceuticals.
dr. Kai Joachimsen calls for a far-reaching and faster implementation of the EU plans. This is the only way to expand Europe in international competition. It remains to be seen how the European Commission will react to the criticism of the BPI.
Here you will find a summary of the most important information:
| Topic | Information |
| ——————- | ———————————————————- |
| Biotechnology strategy | European Commission publishes strategy for biotechnology |
| Criticism of the BPI | Dr. Kai Joachimsen criticizes missing concrete measures |
| Location advantage | Biotechnology as a handicraft of health care |
| Biopharmaceuticals | The proportion increases continuously, many companies in Germany |
| EU strategy | Names important points, but does not respond to some questions |
| Request of the BPI | Extreme and faster implementation of the EU plans |
Source: bpi Federal Association of the pharmaceutical industry/ots